Prescription-drug policy: Remove obstacles keeping alternatives from reaching the market

We’ve focused in the first two posts of this three-part series addressing prescription-drug policy (here and here) on proposals in the United States Senate which offer solutions in search of problems, harm competition and allow brand-name drug companies to continue keep life-saving generics off the market for longer periods of time – all  with costly…

Prescription-drug policy: Don’t give the FDA power over standards for biosimilar medicine

While Kentucky Senator and Majority Leader Mitch McConnell’s proposal to raise the legal age of purchasing tobacco has received a large share of attention regarding the suite of healthcare proposals currently being considered in the U.S. Senate, other issues affecting cost and access to health care – including for prescription drugs – must be carefully…